(Q37909373)

25 August 2017

1 reference

title

Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies (English)

1 reference

25 August 2017

Daniel C Christoph

1

1 reference

25 August 2017

Martin Schuler

series ordinal

2

1 reference

25 August 2017

publication date

1 July 2011

1 reference

Expert Review of Anticancer Therapy

25 August 2017

published in

1 reference

25 August 2017

volume

11

1 reference

25 August 2017

issue

7

1 reference

25 August 2017

page(s)

1115-1130

1 reference

Targeting cell cycle kinases and kinesins in anticancer drug development.

25 August 2017

cites work

1 reference

Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells

21 January 2018

1 reference

Polo-like kinases and oncogenesis

21 January 2018

1 reference

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

21 January 2018

1 reference

Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1.

21 January 2018

1 reference

Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity

21 January 2018

1 reference

Targeting polo-like kinase 1 for cancer therapy.

21 January 2018

1 reference

The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus

21 January 2018

1 reference

Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions

21 January 2018

1 reference

Progress in the discovery of polo-like kinase inhibitors.

21 January 2018

1 reference

Polo-like kinases and the orchestration of cell division

21 January 2018

1 reference

Polo-like kinase 1 reaches beyond mitosis--cytokinesis, DNA damage response, and development

21 January 2018

1 reference

Polo-like-kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stress

21 January 2018

1 reference

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells

21 January 2018

1 reference

PLK1 inhibitors: setting the mitotic death trap.

21 January 2018

1 reference

Scytonemin--a marine natural product inhibitor of kinases key in hyperproliferative inflammatory diseases

21 January 2018

1 reference

The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore

21 January 2018

1 reference

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

Structure of the catalytic domain of human polo-like kinase 1

21 January 2018

1 reference

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

21 January 2018

1 reference

Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.

21 January 2018

1 reference

Longitudinal analysis of heart and liver iron in thalassemia major

21 January 2018

1 reference

Phase II study of erlotinib in patients with advanced biliary cancer

21 January 2018

1 reference

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

21 January 2018

1 reference

The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial

21 January 2018

1 reference

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Res

21 January 2018

1 reference

BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity

21 January 2018

1 reference

A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer

21 January 2018

1 reference

A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies

21 January 2018

1 reference

Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies

21 January 2018

1 reference

Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia.

21 January 2018

1 reference

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

21 January 2018

1 reference

Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.

21 January 2018

1 reference

A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.

21 January 2018

1 reference

In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176

21 January 2018

1 reference

Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors

21 January 2018

1 reference

Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors

21 January 2018

1 reference

Probing cell-division phenotype space and Polo-like kinase function using small molecules

21 January 2018

1 reference

Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases

21 January 2018

1 reference

Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).

21 January 2018

1 reference

A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis

21 January 2018

1 reference

Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition

21 January 2018

1 reference

Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis

21 January 2018

1 reference

Targeted anti-mitotic therapies: can we improve on tubulin agents?

21 January 2018

1 reference

Discovery of thiophene inhibitors of polo-like kinase

21 January 2018

1 reference

Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.

21 January 2018

1 reference

Genome-wide genetic analysis of polyploidy in yeast

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.11.61

1 reference

25 August 2017

1 reference